Borderline products

Although it may be immediately obvious that a product is a medicine and should be regulated as such, some products are more difficult to distinguish from medicines or medical devices and may function for a medicinal purpose and another purpose, such as a cosmetic purpose. For these products, the classification is not immediately clear and multiple regulatory frameworks may apply. For example, it may be uncertain whether a more complex healthcare product might be viewed as a medical device, cosmetic, food, dietary supplement, herbal medicine or biocidal product. Sometimes it is certain circumstances or if certain criteria are met or even claims made about the product’s use that might cause it to be classified as a medicinal product, so it can be unclear which regulatory framework one should comply with for an effective regulatory strategy. These products are called borderline products until their status has been decided.

The regulatory classification of a product can have important ramifications, for example, on how the product is regulated (and by whom), how long it will take before such product can be commercialised (especially if pre-market approval is required), how the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

MDCG Guidance on Performance Studies for In Vitro Diagnostic Medical Devices

The Medical Device Coordination Group (MDCG) has issued a comprehensive guidance document, endorsed in June 2025, addressing performance studies of in vitro diagnostic medical devices under Regulation (EU) 2017/746. The document, developed by representatives from all Member States and chaired by a representative of the European Commission, delineates the applicable regulatory framework and procedures. It clarifies the definitions and distinctions between analytical and clinical performance studies, stipulates when a device is deemed an in vitro diagnostic medical device (IVD) and consequently subject to the Regulation, and sets out responsibilities regarding the assignment of intended purpose and conduct of performance studies. The guidance details the requirements for application or notification to competent authorities, including specific scenarios such as studies involving surgically invasive sample-taking, companion diagnostics, and left-over samples, alongside the relevant articles of the Regulation. It further provides practical instructions on documentation, submission requirements, safety reporting, and the handling of substantial modifications. The document serves as a harmonised reference for sponsors of performance studies, clinical investigators, and manufacturers, ensuring compliance with the IVDR, while underscoring the importance of adhering to both European and national legislative requirements in the conduct of performance studies.

View Life Sciences by content type :

Popular documents